Update on the Diagnosis and Management of Neurocysticercosis

Camille M. Webb, A. Clinton White

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Neurocysticercosis is an important cause of seizures worldwide and is endemic in most of Latin America, Sub-Saharan Africa, Southeast Asia, India, and China. Neurocysticercosis has profoundly different disease manifestations varying from asymptomatic presentation to life-threatening hydrocephalus. Clinical manifestations, pathogenesis, diagnostic methods, and optimal treatment vary with the location, number of lesions, and host response. Diagnosis is based on a combination of clinical presentation, neuroimaging findings, history of exposure, and serologic testing. Initial therapy should be focused on symptom management including seizure control and management of increased intracranial pressure. Emerging data are demonstrating that the optimal management approach varies with stage. Single enhancing or cystic lesions should be treated with albendazole and steroids. Patients with more than two cystic lesions should be treated with combination therapy with albendazole and praziquantel, whereas patients with hydrocephalus benefit from surgical management, especially with minimally invasive approaches.

Original languageEnglish (US)
Article number44
JournalCurrent Infectious Disease Reports
Volume18
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Neurocysticercosis
Albendazole
Hydrocephalus
Seizures
Praziquantel
Southeastern Asia
Latin America
Africa South of the Sahara
Intracranial Pressure
Neuroimaging
India
China
Therapeutics
Steroids

Keywords

  • Albendazole
  • Cysticercosis
  • Neurocysticercosis
  • Praziquantel
  • Taenia solium

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Update on the Diagnosis and Management of Neurocysticercosis. / Webb, Camille M.; White, A. Clinton.

In: Current Infectious Disease Reports, Vol. 18, No. 12, 44, 01.12.2016.

Research output: Contribution to journalReview article

@article{244096ee60404dffa824970e410feead,
title = "Update on the Diagnosis and Management of Neurocysticercosis",
abstract = "Neurocysticercosis is an important cause of seizures worldwide and is endemic in most of Latin America, Sub-Saharan Africa, Southeast Asia, India, and China. Neurocysticercosis has profoundly different disease manifestations varying from asymptomatic presentation to life-threatening hydrocephalus. Clinical manifestations, pathogenesis, diagnostic methods, and optimal treatment vary with the location, number of lesions, and host response. Diagnosis is based on a combination of clinical presentation, neuroimaging findings, history of exposure, and serologic testing. Initial therapy should be focused on symptom management including seizure control and management of increased intracranial pressure. Emerging data are demonstrating that the optimal management approach varies with stage. Single enhancing or cystic lesions should be treated with albendazole and steroids. Patients with more than two cystic lesions should be treated with combination therapy with albendazole and praziquantel, whereas patients with hydrocephalus benefit from surgical management, especially with minimally invasive approaches.",
keywords = "Albendazole, Cysticercosis, Neurocysticercosis, Praziquantel, Taenia solium",
author = "Webb, {Camille M.} and White, {A. Clinton}",
year = "2016",
month = "12",
day = "1",
doi = "10.1007/s11908-016-0547-4",
language = "English (US)",
volume = "18",
journal = "Current Infectious Disease Reports",
issn = "1523-3847",
publisher = "Current Science, Inc.",
number = "12",

}

TY - JOUR

T1 - Update on the Diagnosis and Management of Neurocysticercosis

AU - Webb, Camille M.

AU - White, A. Clinton

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Neurocysticercosis is an important cause of seizures worldwide and is endemic in most of Latin America, Sub-Saharan Africa, Southeast Asia, India, and China. Neurocysticercosis has profoundly different disease manifestations varying from asymptomatic presentation to life-threatening hydrocephalus. Clinical manifestations, pathogenesis, diagnostic methods, and optimal treatment vary with the location, number of lesions, and host response. Diagnosis is based on a combination of clinical presentation, neuroimaging findings, history of exposure, and serologic testing. Initial therapy should be focused on symptom management including seizure control and management of increased intracranial pressure. Emerging data are demonstrating that the optimal management approach varies with stage. Single enhancing or cystic lesions should be treated with albendazole and steroids. Patients with more than two cystic lesions should be treated with combination therapy with albendazole and praziquantel, whereas patients with hydrocephalus benefit from surgical management, especially with minimally invasive approaches.

AB - Neurocysticercosis is an important cause of seizures worldwide and is endemic in most of Latin America, Sub-Saharan Africa, Southeast Asia, India, and China. Neurocysticercosis has profoundly different disease manifestations varying from asymptomatic presentation to life-threatening hydrocephalus. Clinical manifestations, pathogenesis, diagnostic methods, and optimal treatment vary with the location, number of lesions, and host response. Diagnosis is based on a combination of clinical presentation, neuroimaging findings, history of exposure, and serologic testing. Initial therapy should be focused on symptom management including seizure control and management of increased intracranial pressure. Emerging data are demonstrating that the optimal management approach varies with stage. Single enhancing or cystic lesions should be treated with albendazole and steroids. Patients with more than two cystic lesions should be treated with combination therapy with albendazole and praziquantel, whereas patients with hydrocephalus benefit from surgical management, especially with minimally invasive approaches.

KW - Albendazole

KW - Cysticercosis

KW - Neurocysticercosis

KW - Praziquantel

KW - Taenia solium

UR - http://www.scopus.com/inward/record.url?scp=84994051898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994051898&partnerID=8YFLogxK

U2 - 10.1007/s11908-016-0547-4

DO - 10.1007/s11908-016-0547-4

M3 - Review article

VL - 18

JO - Current Infectious Disease Reports

JF - Current Infectious Disease Reports

SN - 1523-3847

IS - 12

M1 - 44

ER -